請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

PR Newswire (美通社)

更新於 13小時前 • 發布於 14小時前 • PR Newswire

SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China's National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA).

7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements:

  • Mab0727: A highly specific CDH17 monoclonal antibody with rapid internalization properties, cross-species (human/monkey) moderate affinity, and minimal off-target binding.
  • Novel cleavable linker: Ensures precise payload release in tumor tissues.
  • MF-6 payload: A proprietary DNA topoisomerase I inhibitor designed to overcome multidrug resistance (MDR), exhibiting superior plasma stability, controlled drug release, and potent bystander effects.

In July 2025, Mabwell published preclinical data in Cell Reports Medicine ("Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor"), demonstrating 7MW4911's tumor-selective cytotoxicity via CDH17-mediated internalization. Key advantages include:

  • Optimized molecular design: Homogeneous drug-to-antibody ratio (DAR=4, >95%) and stable linker confer exceptional plasma stability, while membrane-permeable MF-6 drives potent bystander killing.
  • Broad Antitumor Efficacy: Demonstrates robust tumor regression in colorectal, gastric, and pancreatic cancer PDX/CDX models, including tumors with RAS/BRAF mutations and diverse Consensus Molecular Subtypes (CMS).
  • MDR resistance: Outperforms MMAE/DXd-based ADCs in ABC transporter-mediated MDR models and reverses tumor progression post-ADC treatment.
  • Target versatility: Active even in tumors with low-to-moderate CDH17 expression, expanding potential patient eligibility.
  • Favorable safety profile: Limited tissue distribution in mice, controllable pharmacokinetics (moderate half-life, no accumulation), and a wide therapeutic window in cynomolgus monkeys, with no significant toxicity signals.

With this profile, 7MW4911 emerges as a promising therapeutic candidate for advanced gastrointestinal cancers.

About CDH17

CDH17 is a pan-cancer validated target with restricted expression in normal intestinal epithelium but marked overexpression in gastrointestinal cancers (e.g., colorectal, gastric, pancreatic). Its aberrant expression correlates with tumor metastasis and poor prognosis, positioning it as an ideal therapeutic target.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell's mission is "Explore Life, Benefit Health" and its vision is "Innovation, from ideas to reality". For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

查看原始文章

"Hong Kong Cat Expo 2025" Officially Opens

PR Newswire (美通社)

Honoring our Past, Celebrating our Present, Inspiring our Future with The BrandLaureate 20th Anniversary Special Limited Edition BESTBRANDS Awards 2025.

PR Newswire (美通社)

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

最新內容

China renews alerts for rainstorms, high temperature

XINHUA

Update: Film on Nanjing Massacre tops 1 billion yuan, leading China's summer box office

XINHUA

Xinhua News | 4 killed in bar shooting in U.S. Montana, search for suspect ongoing

XINHUA

Film on Nanjing Massacre tops 1 billion yuan, leading China's summer box office

XINHUA

Xinhua News | China's central bank pledges stronger support for innovation, consumption in H2

XINHUA

LensToLens | Buenos Aires launches first all-electric-bus line with Chinese vehicles

XINHUA

Xinhua Photo Daily | Aug. 2, 2025

XINHUA

Asia Album: National Day celebrations in Singapore

XINHUA

Cambodia, Thailand to mull over border issue in Malaysia next week

XINHUA

BLUETTI Apex 300 Launches in Retail After Raising $5.4M, Leading 2025's Crowdfunding Charts

PR Newswire (美通社)

Japan logs dangerous heat of 40 degrees Celsius for 3rd day

XINHUA

Cambodia's Angkor makes 28.6 mln USD from ticket sales during Jan.-July period

XINHUA

Roundup: Qin Haiyang completes breaststroke golden double while Ibarra ends China's golden run in 3m springboard at Worlds

XINHUA

Macao marks 100-day countdown to National Games with citywide events

XINHUA

Kepler's Forerunner K2 "Bumblebee" Robot Completes 8-Hour Livestream at WAIC 2025, signaling major step toward real-world deployment of embodied AI in industrial settings

PR Newswire (美通社)

Golden Harvest by Karatokay Lake, Xinjiang

XINHUA

Dual-use bridge: subway trains, cars run side-by-side on SW China bridge

XINHUA

UN chief presents proposals for review of mandate implementation

XINHUA

Global AI Data Center Infrastructure Leader Zettabyte Receives Strategic Investment from Lam Capital

PR Newswire (美通社)

NASA, SpaceX launch new crew rotation mission to space station

XINHUA

Full Truck Alliance Co. Ltd. Announces Changes to Its Freight Brokerage Service

PR Newswire (美通社)

Iran to set up "defense council," says media

XINHUA

Palestine wants demilitarized Palestinian state, including Gaza: Abbas

XINHUA

Harbour City Shopping Mall Unveils Hong Kong's Grandest 50th Anniversary Celebration for My Melody, Kiki & Lala

PR Newswire (美通社)

Eurozone inflation holds steady at 2 pct in July, despite regional variations

XINHUA

FNZ Directors Move to Silence Employee Shareholders Behind USD $4.6 Billion Class Action

PR Newswire (美通社)

Tourism contributes nearly 12 pct of Portugal's economy in 2024, but growth impact slows

XINHUA

InPics: 100-day countdown to China's 15th National Games

XINHUA

Mexico's Osmar Olvera Ibarra wins men's 3m springboard gold at Singapore Worlds

XINHUA

Qin Haiyang admits not "fully back" despite Singapore golden double

XINHUA

Noah Holdings and ARK Wealth Hosts Inaugural Global Chinese Wealth Management and Inheritance Summit in Singapore

PR Newswire (美通社)

FIVB President tells local amateurs to "keep enjoying the game" at men's VNL Finals

XINHUA

"Hong Kong Cat Expo 2025" Officially Opens

PR Newswire (美通社)

Chinese vice premier urges all-out efforts to tackle Chikungunya fever outbreak

XINHUA

Elegoo Wraps the First Phase of "ELEGOO With Her", Spotlighting Women Creators in Home Decor, Fashion, Cosplay, and Education

PR Newswire (美通社)

BingX Labs Marks One Year of Web3 & AI Innovation with $16Million in Strategic Investments

PR Newswire (美通社)

From CBA to Spanish Basketball League, Chinese center Yu embarks on a new journey

XINHUA

China reports dramatic H1 surge in cruise passenger throughput

XINHUA

Navigating Globalization: Dialogue on How GAC is Evolving with Technology and Talent

PR Newswire (美通社)